Gilead Sciences’ long-acting drug to block HIV has the potential to end the AIDS epidemic worldwide. But accessibility ...

Even after decades of research, there is no cure for the disease HIV causes, AIDS. But lenacapavir, born out of research on ...

Leading data and analytics company GlobalData’s report, Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast, ...

The global HIV market is expected to reach $32.1 billion by 2033, driven by long-acting injectables and innovative therapies, ...

Gilead Sciences’ long-acting drug to block HIV can end the AIDS epidemic worldwide. But accessibility is the question. © 2025 American City Business Journals. All ...

O'Day emphasized the upcoming FDA decision for Lenacapavir for PrEP, expected by June 19, 2025, and its potential launch in the U.S. shortly thereafter. This is one of nine HIV product launches ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) missed Wall Street’s revenue expectations in Q1 CY2025, with sales ...

Dozens of trials on HIV ground to a halt in February after US President Donald Trump abruptly pulled crucial funding.

The FDA granted Priority Review to lenacapavir for the prevention of HIV as pre-exposure prophylaxis (PrEP). Lenacapavir is a long-acting HIV-1 capsid inhibitor administered as a twice-yearly ...

Announcing a new publication for Acta Materia Medica journal. The HIV-1 capsid protein (CA) plays a crucial role in viral ...

There are several ways to address HIV in homeless populations, with the most promising being the low barrier care model, ...

Why it matters: Gilead's stable outlook amid two key uncertainties—potential pharmaceutical tariffs and the upcoming launch of lenacapavir for the prevention of HIV—was reassuring. Gilead has ...